Keyphrases
Between-group
7%
BRCA2
7%
Cancer Population
7%
CDK12
7%
Clinical Outcomes
100%
Confidence Interval
7%
Dominant Negative
14%
Dominant-negative mutant
14%
Genetic Features
7%
Genetic Modification
7%
Genetic Profile
100%
Gleason
7%
Hazard Ratio
7%
Homologous Recombination Deficiency
7%
Improved Outcomes
7%
Local Therapy
7%
Loss Function
14%
Median Progression-free Survival
7%
Metachronous
7%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Molecular Features
7%
Multivariate Analysis
7%
Multivariate Cox Proportional Hazard Regression
7%
Overall Survival
42%
Progression-free Survival
14%
Prostate Cancer Patients
7%
Single-center Retrospective Study
7%
SPOP mutation
14%
Strong Predictor
7%
Subgroup Analysis
7%
TP53 Alterations
14%
TP53 mutation
21%
Tumor Protein p53 (TP53)
21%
Univariate Analysis
7%
Biochemistry, Genetics and Molecular Biology
BRCA2
16%
Genetics
16%
Genomics
100%
Homologous Recombination
16%
Multivariate Analysis
16%
Overall Survival
100%
Progression Free Survival
50%
Retrospective Study
16%
SPOP
50%
Medicine and Dentistry
BRCA2
7%
Diseases
7%
Hazard Ratio
7%
Homologous Recombination
7%
Local Therapy
7%
Multivariate Analysis
7%
Overall Survival
42%
Progression Free Survival
21%
Proportional Hazards Model
7%
Prostate Cancer
100%
Retrospective Study
7%
Subgroup Analysis
7%
Univariate Analysis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
7%
Overall Survival
42%
Progression Free Survival
21%
Prostate Cancer
100%
Retrospective Study
7%